fortressbio1.jpg
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
14 mai 2024 08h30 HE | Fortress Biotech, Inc.
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...
logo Anervea.png
A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anervea
17 mars 2024 09h19 HE | ANERVEA DATA LABS PRIVATE LIMITED
Pune, March 17, 2024 (GLOBE NEWSWIRE) -- The recent FDA approval of Resmetirom, developed by Madrigal Pharmaceuticals, has sent ripples of excitement throughout the medical community, marking a...
Liver Transplantation Market at 7.1% CAGR to Reach US$2.4 Billion by 2030, Persistence Market Research
24 janv. 2024 13h25 HE | Persistence Market Research
New York, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The global liver transplantation market is projected to experience a compound annual growth rate (CAGR) of 7.1%, translating to an increase from US$ 1.5...
fortressbio1.jpg
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
11 août 2022 08h00 HE | Fortress Biotech, Inc.
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...